TCRX 8-K 2026-09-30
TScan Therapeutics, Inc. (TCRX) 8-K dated 2026-09-30 — accession 0001193125-26-409199.
TScan Therapeutics, Inc. (TCRX) is a biotechnology company listed on NASDAQ.
TScan Therapeutics, Inc. filed a 8-K on 2026-09-30. Accession 0001193125-26-409199.
This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported TCRX revenue for 2025-12-31 was $10.3M. Net income was -$129.8M. Revenue was up 266.7% from 2024-12-31 to 2025-12-31. TCRX currently screens at market cap $62.1M.
Not investment advice. The TCRX SEC hub lists recent forms. The stock page is the research view.